Silence Therapeutics plc

Regulatory Filings • May 14, 2020

National Storage Mechanism | Additional information

RNS Number : 8368M

Silence Therapeutics PLC

14 May 2020

Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Virtual Conference

14 May 2020

LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that Dr. Rob Quinn, Chief Financial Officer, will be participating in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference.

Date:		Wednesday, May 20, 2020
Time:		10:55 am EDT (15:55 BST)
Webcast link:		Silence Therapeutics fireside chat

A live webcast of the event can be accessed via the Investors section of the Company's website at

www.silence-therapeutics.com. An archived replay of the webcast will be available for 60 days on the Company's website after the conference.

For more information, please contact:

Silence Therapeutics plc Iain Ross, Executive Chairman Rob Quinn, Chief Financial Officer	Tel:  +44 (0)20 3457 6900
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson	Tel:  +44 (0)20 7418 8900
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray [email protected]	Tel: +44 (0) 20 3709 5700
U.S. IR Westwicke Peter Vozzo [email protected]	Tel: +1 (443) 213-0505

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

NRAAJMLTMTIBBLM